摘要
神经元一氧化氮合酶(nNOS)生成关键信号递质一氧化氮(NO)。这种气态的自由基分子调节着大量生物过程,从血压到免疫反应和神经信号级联反应。NO的过剩牵扯到一些疾病,包括老年痴呆,帕金森病和精神分裂症。因此nNOS抑制剂为这些疾病的治疗提供了一个潜在的治疗方法。但是因为一氧化氮合酶NOS存在内皮型NOS(eNOS)和诱导型NOS(iNOS)两种亚型,这使得nNOS抑制剂的治疗变得更为复杂。因此nNOS抑制剂的选择性是治疗发展的关键关注点。这篇综述探究了选择性nNOS抑制剂领域的最新进展,特别关注了用于具有更好药动性能的选择性nNOS配体的合理设计的计算方法。这些配体靶向于nNOS酶的4个关键结合点:四氢生物蝶呤,钙调蛋白,烟酰胺腺嘌呤二核苷酸磷酸(NADPH)和精氨酸的结合点。我们会依次介绍这些结合点和抑制它们的化合物以及应用于nNOS抑制领域的计算方法。
关键词: 结合袋,in silico,神经元一氧化氮合酶(nNOS),选择性抑制
Current Medicinal Chemistry
Title:Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations
Volume: 22 Issue: 21
Author(s): Adam M. Curtin, Gemma K. Kinsella and John C. Stephens
Affiliation:
关键词: 结合袋,in silico,神经元一氧化氮合酶(nNOS),选择性抑制
摘要: Neuronal nitric oxide synthase (nNOS) produces the key signalling mediator nitric oxide, (NO). This gaseous, free radical molecule modulates a vast array of biological processes, from vascular pressure to immune responses and neurological signalling cascades. Overproduction of NO has been implicated in conditions including Alzheimer’s disease, Parkinson’s disease and schizophrenia. Inhibition of nNOS therefore offers a potential therapeutic approach for treatment of these conditions. This endeavour is made more complex by the fact that there are two other isoforms of nitric oxide synthase (NOS), endothelial NOS (eNOS) and inducible NOS (iNOS). The selectivity of nNOS inhibitors is therefore a key concern for therapeutic development. This review explores recent advances in the field of selective nNOS inhibition. A particular focus is placed on computational approaches towards the rational design of selective nNOS ligands with improved pharmacokinetic properties. These ligands have been targeted at four key binding sites of the nNOS enzyme - the tetrahydrobiopterin, calmodulin, nicotinamide adenine dinucleotide phosphate (NADPH) and arginine binding sites. The binding sites, and the compounds used to inhibit them, will be discussed in turn, along with the computational methods which have been employed in the field of nNOS inhibition.
Export Options
About this article
Cite this article as:
Adam M. Curtin, Gemma K. Kinsella and John C. Stephens , Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations, Current Medicinal Chemistry 2015; 22 (21) . https://dx.doi.org/10.2174/0929867322666150429112600
DOI https://dx.doi.org/10.2174/0929867322666150429112600 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Augmentation Therapy with Alpha1-antitrypsin: Novel Perspectives
Cardiovascular & Hematological Disorders-Drug Targets Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Sexual Dimorphism in Autoimmune Disease
Current Molecular Medicine Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides
Current Pharmaceutical Design Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Harnessing CD36 to Rein in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypotensive Natural Products: Current Status
Mini-Reviews in Medicinal Chemistry Comparative Analysis of the Rabbit Endothelial Progenitor Cells from Bone Marrow and Peripheral Blood Treated with Selenium Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design Anti-Inflammatory Therapeutic Approaches to Reduce Acute Atherosclerotic Complications
Current Pharmaceutical Biotechnology Cyclosporin A: A Therapeutic Strategy in Allergic Diseases
Letters in Drug Design & Discovery Interleukin-21 in Immune and Allergic Diseases
Inflammation & Allergy - Drug Targets (Discontinued) RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Somatostatin: A Hormone for the Heart?
Current Vascular Pharmacology Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology Beneficial Role of Vitexin and Isovitexin Flavonoids in the Vascular Endothelium and Cardiovascular System
Current Nutraceuticals